The price of LIVN is predicted to go up -18.41%, based on the high correlation periods with SAM. The similarity of these two price pattern on the periods is 96.91%.
LIVN
SAM
LivaNova continues to enjoy a large footprint in the heart-lung machine market, which comes with the sale of consumable oxygenators.
If vagus nerve stimulation proves effective for sleep apnea, this could be a large growth opportunity for LivaNova.
LivaNova has developed expertise in smaller, more niche markets, which helps insulate the business from more intense competition seen elsewhere in medtech.
Needham
2024-11-25
Price Target
$75
Upside
+44.93%
Baird
2024-10-31
Price Target
$66 → $72
Upside
+39.48%
Goldman Sachs
2024-10-04
Price Target
$65
Upside
+20.75%